David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre and Honorary Consultant Nephrologist at the Freeman Hospital’s Renal Services Centre.National Renal Complement Therapeutics Centre
National Renal Complement Therapeutics Centre
David Kavanagh heads the National Renal Complement Therapeutics Centre (NRCTC) – a combined clinical, diagnostic, research and treatment centre for the complement mediated diseases:
- atypical haemolytic uraemic syndrome (aHUS) and
- C3 glomerulopathy (C3G).
In 2016, after a competitive tendering process, NHS England awarded the NRCTC the contract to run the national aHUS and C3G services. The NRCTC delivers this fully integrated care pathway to expedite optimal management of patients with aHUS and C3G on a shared-care basis with the referring clinicians.
- Atypical Haemolytic Uraemic Syndrome,
- C3 Glomerulopathy,
- Complement-related renal disease,
- Age-related macular degeneration (AMD),
- Complement biology,
- Translational Medicine,
- Retinal Vasculopathy with Cerebral Leucodystrophy (RVCL),
- Glomerulonephritis and Vasculitis.
Follow us on twitter at @NationalaHUS
Professor Kavanagh also runs glomerulonephritis and vasculitis clinic at Freeman Hospital’s Renal Services Centre.
Professor Kavanagh moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis.
He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award.
His research group at Newcastle University investigates complement in renal and retinal diseases and is fully integrated with the NRCTC to provide rapid translational benefits to patients. He is also academic founder of Gyroscope Therapeutics which was the first to use gene therapy in clinical trials to attempt to halt the commonest cause of blindness in the developed world- Age Relate Macular Degeneration.Renal services